ERBB2 and neoplasm: Indeed, in 29% of TN tumours BRCA1 promoter was hypermethylated compared to 5% of HR-positive/HER2-negative and 2% of HER2-positive tumours, consistent with the 36.7% reported by Veek et al. in 68 non-inherited TN breast cancers [36].